InMed Pharmaceuticals (INM) Profit After Tax Growth (3y) (2022 - 2026)
InMed Pharmaceuticals (INM) Profit After Tax Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | 14.01% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | 2.89% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 15.37% |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.64 Mn | 1.40 Mn | - | -14.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.08% |
| Dec 31, 2025 | 1.17% |
| Sep 30, 2025 | 21.06% |
| Jun 30, 2025 | 38.84% |
| Mar 31, 2025 | 15.18% |
| Dec 31, 2024 | 15.60% |
| Sep 30, 2024 | 17.35% |
| Jun 30, 2024 | 15.02% |
| Mar 31, 2024 | 21.79% |
| Dec 31, 2023 | 8.71% |
| Sep 30, 2023 | -16.63% |
| Jun 30, 2023 | 31.43% |
| Mar 31, 2023 | 10.01% |
| Dec 31, 2022 | 5.55% |
| Sep 30, 2022 | -3.96% |